![Boston_H_color[33632]_edited.png](https://static.wixstatic.com/media/e60c5c_0b72738a80554196840094a8e387c5ed~mv2.png/v1/fill/w_338,h_77,al_c,q_85,usm_0.66_1.00_0.01,enc_avif,quality_auto/Boston_H_color%5B33632%5D_edited.png)
Registration Information
Date: Wednesday, April 28, 2021 Start Time: 12:00 PM ET Speaker(s): John Pagel, MD, PhD Hosted by: Amanda Erickson Program Topic: Epizyme Educational Program Virtual Webcast
TAZVERIK® (tazemetostat) is indicated for the treatment of:
• Adult patients with relapsed or refractory (R/R) follicular
lymphoma (FL) whose tumors are positive for an EZH2
mutation as detected by an FDA-approved test and who
have received at least 2 prior systemic therapies
• Adult patients with R/R FL who have no satisfactory
alternative treatment options
These indications are approved under accelerated approval based on overall response rate and duration of response. Continued approval for these indications may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
Comments